Evidence map›Paper›PMID 29075104›Full record

SynthesisDrug design, development and therapy2017

Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials.

Jian Xin Zhou, Li Jin Feng, Xi Zhang

Abstract readMeta-AnalysisReview
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Drug design, development and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 7 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 7 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 7 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Drug-specific differences in fatal adverse events among PARP inhibitors: a FAERS pharmacovigilance study.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Retrospective Analysis ofJCO precision oncology · 2025
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

3 authors.

Jian Xin Zhou *Department of Gynecology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing.
Li Jin Feng *Department of Pathology, Shanghai Tenth People's Hospital, Tongji University, School of Medicine, Shanghai.
Xi ZhangDepartment of Radiation Oncology, Affiliated Hospital of Hebei University, Baoding, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeHematologic toxicities, including neutropenia, thrombocytopenia, and anemia, are major adverse effects of PARP inhibitors (PARPis), but the incidence rate and overall risk has not been systematically studied. Therefore, we conducted a meta-analysis of published clinical trials to investigate the incidence and relative risks (RRs) of severe (high-grade) hematologic events in cancer patients treated with PARPis.

methodsPubMed, Embase, and oncology conference proceedings were searched for relevant studies. Eligible studies were Phase II and III randomized controlled trials (RCTs) of PARPis in cancer patients with adequate safety data on hematologic toxicities. The summary incidence, RRs, and 95% confidence intervals (CIs) were calculated.

resultsA total of 2,479 patients from 12 RCTs revealed that the incidence of PARPi-associated severe hematologic toxicities was, respectively: neutropenia: 32.9% (95% CI, 20.5%-48.3%); thrombocytopenia: 15.9% (95% CI, 9.5%-25.4%), and anemia: 9.1% (95% CI, 5.1%-15.7%). Olaparib was associated with an increased risk of severe neutropenia. Veliparib was associated with an increased risk of severe neutropenia and thrombocytopenia. Niraparib was associated with an increased risk of severe thrombocytopenia, anemia, and neutropenia. When stratified by combination therapy, significantly increased risk of hematologic toxicities was observed for patients treated with PARPis monotherapy and PARPis combined with single-agent chemotherapy.

conclusionTreatment with PARPis olaparib, veliparib, and niraparib is associated with a significant increase in the risk of hematologic toxicities in cancer patients, and frequent clinical monitoring should be emphasized when managing these PARPis.

Indexed as

AnemiaAntineoplastic AgentsHematologic DiseasesHumansIncidenceNeoplasmsNeutropeniaPoly(ADP-ribose) Polymerase InhibitorsRandomized Controlled Trials as TopicRiskThrombocytopeniaAntineoplastic AgentsPoly(ADP-ribose) Polymerase Inhibitorscancerhematologic toxicitiesmeta-analysisPARP inhibitorsRCTs

Identifiers

PMID29075104
PMCPMC5648323

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.